Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309
Financing led by Orlando Health Ventures includes a prominent group of new and existing investorsFunding supports further development of VGT-309 in lung cancer and other solid tumorsFluorescent agent is designed to enhance tumor visualization during minimally invasive and robotic-assisted cancer surgery October 04, 2022 08:00 AM Eastern Daylight Time MINNEAPOLIS–(BUSINESS WIRE)–Vergent Bioscience, a clinical-stage biotechnology […]